Loading...
Recent advances in androgen-receptor (AR) biology have facilitated development of a new generation of treatments for patients with advanced prostate cancer, including MDV3100, a novel AR antagonist that blocks nuclear translocation and DNA binding of AR. In the phase I/II MDV3100 trial, investigators assessed changes in prostate-specific antigen (PSA) levels, measurable soft tissue and bone metastases, and number of circulating tumor cells (CTCs), as well as time on treatment in 140 patients with castrate-resistant prostate cancer who received MDV3100. At week 12, PSA declines of >50% were seen in 57% and 45% of patients who were chemotherapy naive and chemotherapy pretreated, respectively. Asse…